Cryoport, Inc. reports developments in temperature-controlled supply chain solutions for the life sciences, with recurring updates tied to regenerative medicine and cell and gene therapy support. Its platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, cryopreservation services and cryogenic systems.
Company news commonly covers quarterly and annual operating results, revenue guidance, clinical-trial and commercial therapy support, Life Sciences Services and Life Sciences Products activity, MVE Biological Solutions cryogenic systems, product introductions such as Fusion freezers, and quality or regulatory certifications for therapeutic-cell transport.
Cryoport, Inc. (NASDAQ: CYRX) has appointed Linda Baddour to its Board of Directors, effective March 15, 2021. Baddour brings over twenty years of experience in healthcare and life sciences, having previously served as CFO at PRA Health Sciences. CEO Jerrell Shelton emphasized the importance of governance in enhancing growth through their expanded global footprint. Baddour expressed excitement about joining Cryoport as it capitalizes on opportunities in the growing regenerative therapies market.
Cryoport, Inc. (NASDAQ: CYRX) announced its financial results for Q4 and FY 2020, reporting significant revenue growth across all sectors. Total revenue soared to $48.4 million in Q4 2020, up 423% from the previous year, and reached $78.7 million for the full year, a 132% increase. Key markets include biopharma/pharma with a 378% Q4 growth, and animal health at 2363%. Despite a net loss of $11.5 million in Q4, the company remains optimistic about 2021, supported by acquisitions and a robust pipeline of clinical trials, now totaling 528. Cryoport's ESG initiatives have also been highlighted as part of their strategic vision.
Cryoport, Inc. (NASDAQ: CYRX) announced its financial results for the fourth quarter and fiscal year ended December 31, 2020 will be reported on March 1, 2021, after U.S. markets close. In conjunction with this, a document titled "Cryoport 2020 Year in Review" will be released, highlighting the company's recent performance and operational updates. A conference call is scheduled for 5:00 PM EST the same day to address investor questions regarding the reported results. The call will also be accessible via webcast.
Summary not available.
Cryoport, Inc. (Nasdaq: CYRX) announced the conversion of 50,000 shares of 4.0% Series C Convertible Preferred Stock into common stock by funds affiliated with Blackstone (NYSE: BX). This conversion resulted in 1,312,860 new shares of common stock issued on February 5, 2021, part of Blackstone's original $250 million investment. Cryoport's leadership highlighted the strategic acquisitions of CRYOPDP and MVE Biological Solutions as key factors for future growth in temperature-controlled supply chain solutions, anticipating increased demand in cell and gene therapies.
Cryoport, Inc. (Nasdaq: CYRX) recently completed an underwritten public offering of 4,356,059 shares at $66.00 each, generating approximately $287.5 million in gross proceeds. This offering included an additional 568,181 shares from underwriters' full exercise of their option. The net proceeds will support general corporate purposes such as working capital, inventory development, and infrastructure expansion. The offering was executed under an effective shelf registration statement filed with the SEC.
Cryoport, Inc. (Nasdaq: CYRX) announced a public offering of 3,787,878 newly issued shares at $66.00 per share, aiming for net proceeds of approximately $234.5 million. The offering, which includes a 30-day underwriters' option for an additional 568,181 shares, is expected to close on January 25, 2021. The funds will be used for general corporate purposes, including working capital, inventory development, infrastructure expansion, and marketing. Major banks involved include Morgan Stanley and Jefferies.
Cryoport, Inc. (Nasdaq: CYRX) announced its intention to offer $200 million in common stock through an underwritten public offering, subject to market conditions. The company may grant underwriters a 30-day option for an additional 15% of shares offered. Proceeds will support general corporate purposes, including working capital and infrastructure development. The offering is supported by a previously filed automatic shelf registration with the SEC. Leading investment banks such as Morgan Stanley and Jefferies are managing the offering.
Cryoport, Inc. (CYRX) has signed a three-year agreement with the Colorado Center for Reproductive Medicine (CCRM) to enhance fertility treatments through its temperature-controlled supply chain solutions. The partnership aims to support services such as in vitro fertilization (IVF), fertility preservation, and third-party reproduction by managing cryogenic shipments of human eggs and embryos. CCRM operates 11 centers across North America, employing over 560 staff, including 40 physicians and 22 PhDs. Cryoport will also extend its logistics solutions as CCRM scales operations.
Cryoport, Inc. (NASDAQ: CYRX) reported a solid performance in Q3 2020, with revenues increasing 17% to $11.2 million. The company signed agreements for milestone acquisitions of MVE Biological Solutions and CRYOPDP, expanding global operations to 30 locations. Biopharma revenue rose 12.8% to $8.4 million, while Reproductive Medicine revenue surged 61.6% to $1.2 million. Despite a net loss of $11.4 million, cash reserves increased to $202.9 million due to successful financing activities. The company supports 517 clinical trials and anticipates strong growth entering 2021.